Potassium Channel-blockers as Therapeutic Agents to Interfere with Bone Resorption of Periodontal Disease
Tóm tắt
Inflammatory lesions of periodontal disease contain all the cellular components, including abundant activated/memory T- and B-cells, necessary to control immunological interactive networks and to accelerate bone resorption by RANKL-dependent and -independent mechanisms. Blockade of RANKL function has been shown to ameliorate periodontal bone resorption and other osteopenic disorders without affecting inflammation. Development of therapies aimed at decreasing the expression of RANKL and pro-inflammatory cytokines by T-cells constitutes a promising strategy to ameliorate not only bone resorption, but also inflammation. Several reports have demonstrated that the potassium channels Kv1.3 and IKCa1, through the use of selective blockers, play important roles in T-cell-mediated events, including T-cell proliferation and the production of pro-inflammatory cytokines. More recently, a potassium channel-blocker for Kv1.3 has been shown to down-regulate bone resorption by decreasing the ratio of RANKL-to-OPG expression by memory-activated T-cells. In this article, we first summarize the mechanisms by which chronically activated/memory T-cells, in concert with B-cells and macrophages, trigger inflammatory bone resorption. Then, we describe the main structural and functional characteristics of potassium channels Kv1.3 and IKCa1 in some of the cells implicated in periodontal disease progression. Finally, this review elucidates some recent advances in the use of potassium channel-blockers of Kv1.3 and IKCa1 to ameliorate the clinical signs or side-effects of several immunological disorders and to decrease inflammatory bone resorption in periodontal disease. ABBREVIATIONS: AICD, activation-induced cell death; APC, antigen-presenting cells; B(K), large conductance; CRAC, calcium release-activated calcium channels; DC, dendritic cell; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IFN-γ, interferon-γ; IP3, inositol (1,4,5)-triphosphate; (K)ir, inward rectifier; JNK, c-Jun N-terminal kinase; I(K), intermediate conductance; LPS, lipopolysaccharide; L, ligand; MCSF, macrophage colony-stimulating factor; MHC, major histocompatibility complex; NFAT, nuclear factor of activated T-cells; RANK, receptor activator of nuclear factor-κB; TCM, central memory T-cells; TEM, effector memory T-cells; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; OPG, osteoprotegerin; Omp29, 29-kDa outer membrane protein; PKC, protein kinase C; PLC, phospholipase C; RT-PCR, reverse-transcriptase polymerase chain-reaction; S(K), small conductance; TCR, T-cell receptor; and (K)v, voltage-gated.
Từ khóa
Tài liệu tham khảo
Amigorena S, Choquet D, Teillaud JL, Korn H, Fridman WH -1990- Ion channel blockers inhibit B cell activation at a precise stage of the G1 phase of the cell cycle. Possible involvement of K+ channels. J Immunol 144:2038–2045.
Arkett SA, Dixon J, Yang JN, Sakai DD, Minkin C, Sims SM -1994- Mammalian osteoclasts express a transient potassium channel with properties of Kv1.3. Receptors Channels 2:281–293.
Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR -2001- The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 1:348–360.
Boltchi FE, Rees TD, Iacopino AM -1999- Cyclosporine A-induced gingival overgrowth: a comprehensive review. Quintessence Int 30:775–783.
Brent LH, Butler JL, Woods WT, Bubien JK -1990- Transmembrane ion conductance in human B lymphocyte activation. J Immunol 145:2381–2389.
Flanagan AM, Massay HM -2003- Generating human osteoclasts in vitro from bone marrow and peripheral blood. Methods Mol Med 80:113–128.
Fujihashi K, Yamamoto M, Hiroi T, Bamberg TV, McGhee JR, Kiyono H -1996- Selected Th1 and Th2 cytokine mRNA expression by CD4+ T cells isolated from human gingival tissues. Clin Exp Immunol 103:422–428.
Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, et al. -1994- Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45:1227–1234.
Hille B -2001- Ionic channels of excitable membranes. 3rd ed. Sunderland, MA: Sinauer Associates.
Kajiya H, Okamoto F, Fukushima H, Takada K, Okabe K -2003- Mechanism and role of high-potassium-induced reduction of intracellular Ca2+ concentration in rat osteoclasts. Am J Physiol Cell Physiol 285:C457–C466.
Khoori AH, Einollahi B, Ansari G, Moozeh MB -2003- The effect of cyclosporine with or without nifedipine on gingival overgrowth in renal transplant patients. J Can Dent Assoc 69:236–241.
Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, et al. -1997- Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 158:5120–5128.
Page RC, Schroeder HA -1976- Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Invest 34:235–249.
Partiseti M, Choquet D, Diu A, Korn H -1992- Differential regulation of voltage- and calcium-activated potassium channels in human B lymphocytes. J Immunol 148:3361–3368.
Partiseti M, Korn H, Choquet D -1993- Pattern of potassium channel expression in proliferating B lymphocytes depends upon the mode of activation. J Immunol 151:2462–2470.
Socransky SS, Haffajee AD, Ximenez-Fyvie LA, Feres M, Mager D -2000- Ecological considerations in the treatment of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis periodontal infections. Periodontol 2000 20:341–362.
Sutro JB, Vayuvegula BS, Gupta S, Cahalan MD -1989- Voltage-sensitive ion channels in human B lymphocytes. Adv Exp Med Biol 254:113–122.
Taubman MA, Ebersole JL, Smith DJ -1982- Association between systemic and local antibody and periodontal diseases. In: Host parasite interactions in periodontal diseases. Genco R, Mergenhagen SE, editors. Washington, DC: ASM Press, pp. 283–298.
Taubman MA, Eastcott JW, Shimauchi H, Takeichi O, Smith DJ -1994- Modulatory role of T lymphocytes in periodontal inflammation. In: Molecular pathogenesis of periodontal disease. Genco R, Hamada S, Lehner T, McGhee JR, Mergenhagen SE, editors. Washington, DC: ASM Press, pp. 147–157.
Valverde P, Kawai T, Taubman MA -2004- Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res 19:155–164.
Wilson M -1995- Biological activities of lipopolysaccharides from oral bacteria and their relevance to the pathogenesis of chronic periodontitis. Sci Pro 78:19–34.
Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, et al. -2004- RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49–57.
Wulff H, Beeton C, Chandy KG -2003a- Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 6:640–647.
Yu FH, Catterall WA -2004- The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis. Sci STKE 253:15–20.
Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. -1998- OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161:6113–6121.